Outcomes of Intravenous Ganciclovir Administration via an Outpatient Parenteral Antimicrobial Therapy Program: A Single-Center Experience
Annals of Pharmacotherapy · 2026
DOI: 10.1177/10600280251349570 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2026. Verfasst von Dhruv P Patel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky, Lexington, KY, USA. Hauptthemen laut MEDLINE: Ganciclovir, Antiviral Agents, Cytomegalovirus Infections. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Background
Intravenous (IV) ganciclovir is used in the management of herpesvirus infections, including cytomegalovirus (CMV). Ganciclovir is usually administered inpatient given the need for close monitoring of laboratory parameters.
Objective
This study describes our experience with administering IV ganciclovir via an outpatient parenteral antimicrobial therapy (OPAT) program.
Methods
This is a retrospective review of patients discharged on IV ganciclovir via OPAT at a tertiary medical center from August 2019 to August 2024. Demographics and treatment outcomes were collected.
Results
Ganciclovir was the preferred agent in all patients either due to concern for gastrointestinal absorption or provider preference. Eighteen patients with a median age of 59.5 (interquartile range [IQR]: 53-65) years met criteria. The most common underlying immunocompromising condition was receipt of a transplanted organ in 16 (88.9%) patients, most commonly heart (8 patients) and kidney transplants (7 patients). Median duration of therapy after hospital discharge was 22 (IQR: 20-27) days. Fifteen (83.3%) patients transitioned to valganciclovir on completion of parenteral therapy either as secondary prophylaxis or continuation of therapy. The most common adverse event was leukopenia in 6 (33.3%) patients. One patient developed acute kidney injury (AKI) requiring dose modification and eventual discontinuation. Conclusion and Relevance: Ganciclovir via OPAT is a viable option in patients requiring an extended duration of IV therapy. In our cohort of 18 patients, only one had early discontinuation of therapy due to ganciclovir-related AKI. Close monitoring of labs and an established OPAT protocol can allow for successful completion of therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky, Lexington, KY, USA.
- Department of Pharmacy Services, University of Kentucky, Lexington, KY, USA.
ORCID-Profile: Armaghan-E-Rehman Mansoor
Zitieren
APA
Patel, D. P., Mynatt, R., Logan, A., Villacorta, E., & Mansoor, A. E. (2026). Outcomes of Intravenous Ganciclovir Administration via an Outpatient Parenteral Antimicrobial Therapy Program: A Single-Center Experience. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251349570
Vancouver
Patel DP, Mynatt R, Logan A, Villacorta E, Mansoor AE. Outcomes of Intravenous Ganciclovir Administration via an Outpatient Parenteral Antimicrobial Therapy Program: A Single-Center Experience. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280251349570
BibTeX
@article{Patel2026,
author = {Patel, Dhruv P and Mynatt, Ryan and Logan, Ashley and Villacorta, Evelyn and Mansoor, Armaghan-E-Rehman},
title = {Outcomes of Intravenous Ganciclovir Administration via an Outpatient Parenteral Antimicrobial Therapy Program: A Single-Center Experience},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280251349570}
}
EUVIMED